<DOC>
	<DOCNO>NCT00043628</DOCNO>
	<brief_summary>This two-part study determine whether stem cell ( primitive cell produce bone marrow develop blood cell type cell ) push bloodstream , relocate heart , grow new heart muscle blood vessel patient chest pain cause narrowing coronary ( heart ) artery . The new blood vessel may enable patient activity experience chest pain . Part 1 study evaluate small number patient whether increase white blood cell follow administration G-CSF ( drug use move stem cell bone marrow bloodstream ) safe people coronary heart disease . Part 2 evaluate effect circulate stem cell heart function . Patients 21 year age old coronary artery blockage limit blood flow heart ( show coronary angiography within 6 month enter study ) cause chest pain interferes ability carry daily live activity may eligible study . Candidates screen blood test , exercise test , magnetic resonance imaging ( MRI ) , 24-hour Holter monitor heart rate rhythm . Participants undergo follow test procedure : Part 1 : Patients hospitalize NIH Clinical Center 5 day . On first day admission , indwell catheter ( short plastic tube ) place arm vein avoid multiple needle stick blood sampling . Patients exercise treadmill . Blood sample draw exercise test 2 hour test . The next 2 day , patient receive daily injection G-CSF skin . Blood sample draw every day 5 day monitor effect G-CSF move cell bloodstream . Additional sample draw determine effect G-CSF number stem cell become heart cell , well effect blood clot ability . After discharge hospital , patient return clinic 2 week initiation G-CSF treatment physical examination , blood test , treadmill exercise test . One month initiation treatment , patient return clinic physical examination , blood test , treadmill exercise test , MRI study , fit Holter monitor 24-hour heart monitoring . Part 2 : Patients hospitalize NIH Clinical Center 5 day , undergoing procedure Part 1 , except receive G-CSF 5 day instead 2 . They also undergo procedure detail 2-week 1-month follow-up visit . Then , 3 month return clinic physical examination , routine blood test , treadmill exercise test . This conclude formal participation study . However , patient request return outpatient clinic year follow-up .</brief_summary>
	<brief_title>Stem Cell Mobilization Treat Chest Pain Shortness Breath Patients With Coronary Artery Disease</brief_title>
	<detailed_description>Percutaneous transluminal coronary angioplasty stenting coronary artery bypass surgery effective therapy relief angina cause coronary artery disease ( CAD ) . However many patient CAD fail attempt conventional revascularization remain symptomatic despite optimized anti-ischemic medical therapy . For grow number patient , need novel therapeutic approach . Experimental study animal model indicate primitive pluripotential cell ( 'stem ' cell ) bone marrow may localize ischemic myocardium , differentiate along endothelial , smooth muscle , cardiomyocyte lineage , improve cardiac performance . A recent report suggest granulocyte-macrophage colony stimulate factor , mobilize stem cell bone marrow circulation , may improve collateral blood flow ischemic myocardium patient CAD . The purpose protocol test effectiveness relate cytokine , granulocyte colony stimulate factor ( G-CSF ) , potently mobilize stem cell bone marrow , relief myocardial ischemia improvement myocardial contractility stress patient CAD good candidate conventional revascularization , want attempts conventional revascularization , remain symptomatic medical therapy . Our hypothesis G-CSF improve blood flow myocardium leave ventricular contractile response stress mobilize pluripotential cell bone marrow localization ischemic region heart , result development new artery regeneration contractile cardiomyocytes . The primary end-point Phase I ( safety ) component study absence cardiovascular adverse event associate increase white blood cell count follow G-CSF administration patient CAD . The secondary end-point Phase I determination platelet aggregation coagulation activation G-CSF administration . The primary endpoint Phase II ( efficacy ) component study improvement magnetic resonance imaging ( MRI ) -determined regional leave ventricular contractility gadolinium distribution ( index blood flow ) stress 1 month follow G-CSF administration compare pretreatment baseline measurement . Secondary Phase II end-points include determination 1 ) efficacy stem endothelial progenitor cell ( EPC ) mobilization G-CSF , 2 ) change treadmill exercise duration associate G-CSF treatment . Demonstration safe effective cytokine-induced mobilization stem cell cardiac benefit could result important therapeutic option CAD patient alternative relief myocardial ischemia angina pectoris .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Adults older 21 year . Functional class ( CCS ) 3 4 angina attributable atherosclerotic CAD , despite medical management , optimal mechanical revascularization due coronary anatomy , comorbidity , patient preference . Left ventricular ejection fraction great 30 percent . Inducible myocardial ischemia dobutamine stress MRI . No congestive heart failure symptom within 2 month . No active infection . Normal renal function : creatinine le 1.5 mg/dl , proteinuria le 1plus Normal liver function : bilirubin le 1.5 mg/dl , transaminase within normal limit . Normal blood count : WBC 300010000/microliter , granulocyte great 1500/microliter ; platelet count great 150,000/microliter , Hgb great 12.5 g/dl . Subject understands protocol provide write , informed consent addition willingness comply specify followup evaluation . EXCLUSION CRITERIA : Myocardial infarction within 2 month . Crescendo angina : Angina pectoris prolong duration ( great 30 minute ) , respond nitroglycerin ( 3 tablet ) , occur increase frequency previous two week . Significant structural heart disease ( e.g . hypertrophic dilate cardiomyopathy , valvular heart disease ) determine echocardiography . Patients HIV positive , chronic inflammatory disease , chronic immunosuppressive medication . Women childbearing age unless recent pregnancy test negative . Lactating woman . Known active malignancy prior history hematologic malignancy . Participation unrelated research involve investigational pharmacological agent 30 day plan GCSF dose . Contraindication MRI . Known hypersensitivity E. coliderived protein gadolinium .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>Progenitor Cells</keyword>
	<keyword>MRI</keyword>
	<keyword>Coronary Blood Flow</keyword>
	<keyword>Hematopoiesis</keyword>
	<keyword>Myocardial Contractility</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>CAD</keyword>
	<keyword>Heart Disease</keyword>
</DOC>